Cargando…

Correction to: Prospective randomized pharmacogenetic study of topiramate for treating alcohol use disorder

Detalles Bibliográficos
Autores principales:	Kranzler, Henry R., Morris, Paige E., Pond, Timothy, Crist, Richard C., Kampman, Kyle M., Hartwell, Emily E., Lynch, Kevin G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8209043/ https://www.ncbi.nlm.nih.gov/pubmed/33883700 http://dx.doi.org/10.1038/s41386-021-01013-6

Ejemplares similares

Prospective randomized pharmacogenetic study of topiramate for treating alcohol use disorder
por: Kranzler, Henry R., et al.
Publicado: (2021)

Effects of topiramate on neural responses to alcohol cues in treatment-seeking individuals with alcohol use disorder: preliminary findings from a randomized, placebo-controlled trial
por: Wetherill, Reagan R., et al.
Publicado: (2021)

Survey of Addiction Specialists’ Use of Medications to Treat Alcohol Use Disorder
por: Ehrie, Jarrod, et al.
Publicado: (2020)

A Delta-Opioid Receptor Gene Polymorphism Moderates the Therapeutic Response to Extended-Release Buprenorphine in Opioid Use Disorder
por: Kranzler, Henry R, et al.
Publicado: (2020)

Prescription of topiramate to treat alcohol use disorders in the Veterans Health Administration
por: Del Re, A C, et al.
Publicado: (2013)

Comparison between baclofen and topiramate in alcohol dependence: A prospective study
por: Jose, Nimmi A., et al.
Publicado: (2019)

Topiramate versus naltrexone for alcohol use disorder: study protocol for a genotype-stratified, double-blind randomised controlled trial (TOP study)
por: Morley, Kirsten C., et al.
Publicado: (2018)

Correction to: Comparison of FDA Table of Pharmacogenetic Associations and Clinical Pharmacogenetics Implementation Consortium guidelines
Publicado: (2022)

Correction: Type II Renal Tubular Acidosis Secondary to Topiramate: A Review
por: Sinha, Ankur, et al.
Publicado: (2019)

Replication of the pharmacogenetic effect of rs678849 on buprenorphine efficacy in African-Americans with opioid use disorder
por: Crist*, Richard. C., et al.
Publicado: (2018)

Correction: Evaluating Predictive Pharmacogenetic Signatures of Adverse Events in Colorectal Cancer Patients Treated with Fluoropyrimidines
por: Jennings, Barbara A., et al.
Publicado: (2015)

TOPIRAMATE INDUCED PRURITUS IN A PATIENT WITH ALCOHOL DEPENDENCE
por: Aggarwal, Ashish, et al.
Publicado: (2011)

Pharmacogenetics of alcohol addiction: current perspectives
por: Zastrozhin, M S, et al.
Publicado: (2019)

Glaucoma: Adverse event on use of topiramate in alcohol de-addiction
por: Pai, Keshava, et al.
Publicado: (2011)

Phenotypic Assessment and the Discovery of Topiramate
por: Maryanoff, Bruce E.
Publicado: (2016)

Zonisamide, Topiramate, and Levetiracetam: Efficacy and Neuropsychological Effects in Alcohol Use Disorders
por: Knapp, Clifford M., et al.
Publicado: (2015)

Chronic migraine prevention with topiramate
por: Peres, M. F. P., et al.
Publicado: (2006)

Outcome of topiramate in migraine prophylaxis
por: Ibrahim, Etedal Ahmed A., et al.
Publicado: (2023)

Prevention of Type 2 Diabetes in Subjects With Prediabetes and Metabolic Syndrome Treated With Phentermine and Topiramate Extended Release
por: Garvey, W. Timothy, et al.
Publicado: (2014)

Topiramate in migraine progression
por: Ruiz, Luigi, et al.
Publicado: (2009)

Topiramate-induced nephrolithiasis
por: Giannopoulou, Eleni Z, et al.
Publicado: (2015)

Author Correction: Improving pharmacogenetic prediction of extrapyramidal symptoms induced by antipsychotics
por: Boloc, Daniel, et al.
Publicado: (2019)

Iatrogenic topiramate poisoning in an ICU patient: Focus on topiramate peak time prolongation
por: Hoebregts, Vera M.G., et al.
Publicado: (2021)

Treatment of alcohol dependence with low-dose topiramate: an open-label controlled study
por: Paparrigopoulos, Thomas, et al.
Publicado: (2011)

Correction: Knowledge, perceptions and confidence of physicians and pharmacists towards pharmacogenetics practice in Kuwait
Publicado: (2019)

Topiramate-induced macular neurosensory retinal detachment
por: Rosenberg, Kevin, et al.
Publicado: (2017)

Relationship between tonic and phasic craving for alcohol
por: Hartwell, Emily E., et al.
Publicado: (2018)

Topiramate Monotherapy in Infantile Spasm
por: Kwon, Young-Se, et al.
Publicado: (2006)

Topiramate-Induced Lithium Toxicity
por: Khan, Afaque H, et al.
Publicado: (2017)

Psychopharmacology of topiramate: from epilepsy to bipolar disorder
por: Mula, Marco, et al.
Publicado: (2006)

Correction to: Pharmacogenetic interventions to improve outcomes in patients with multimorbidity or prescribed polypharmacy: a systematic review
por: O’Shea, Joseph, et al.
Publicado: (2022)

Current State and Future Prospects of Direct-to-Consumer Pharmacogenetics
por: Chua, E. W., et al.
Publicado: (2012)

Comprehensive review of visual defects reported with topiramate
por: Ford, Lisa, et al.
Publicado: (2017)

The Search for Medications to Treat Stimulant Dependence
por: Kampman, Kyle M.
Publicado: (2008)

Author Correction: Sex-Related Differences in Impact on Safety of Pharmacogenetic Profile for Colon Cancer Patients Treated with FOLFOX-4 or XELOX Adjuvant Chemotherapy
por: Ruzzo, Annamaria, et al.
Publicado: (2020)

Topiramate in the treatment of partial and generalized epilepsy
por: Faught, Edward
Publicado: (2007)

Topiramate and the vision: a systematic review
por: Abtahi, Mohammad-Ali, et al.
Publicado: (2012)

Assessment of topiramate's efficacy and safety in epilepsy
por: Gupta, Prem P., et al.
Publicado: (2014)

EHMTI-0146. Topiramate in migraine prevention
por: Ristic, S, et al.
Publicado: (2014)

Topiramate-Induced Persistent Eyelid Myokymia
por: Khalkhali, Mohammadrasoul
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_fcptkp16afriobjubgbf3kvhar